Filter by: patients
Home > Community Treatment Reports and Side Effects > ALS Phase 2 Study KNS-760704 Treatment Report
What is ALS Phase 2 Study KNS-760704?

R(+) pramipexole dihydrochloride monohydrate [R(+)PPX], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols. Read more...Click to read more below

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
ALS (Amyotrophic Lateral Sclerosis) 3 0
Other 1 0

See all 2 patients currently using ALS Phase 2 Study KNS-760704

Mouse over the table for more information

Reported Schedules

  2 mg daily 300 mg daily
  1 Number of Patients: 1 2 Number of Patients: 2  

Reported Stop Reasons

Why Patients Stopped Using ALS Phase 2 Study KNS-760704 (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 1   Course of treatment ended: 100%

See all 1 patient who’ve stopped using ALS Phase 2 Study KNS-760704

Reported Duration See details about how long patients take this treatment ▼

Currently Using ALS Phase 2 Study KNS-760704

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Using ALS Phase 2 Study KNS-760704

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Report created on February 11, 2012.